Literature DB >> 14722317

Transport of ethinylestradiol glucuronide and ethinylestradiol sulfate by the multidrug resistance proteins MRP1, MRP2, and MRP3.

Xiao-Yan Chu1, Su-E W Huskey, Matthew P Braun, Balazs Sarkadi, David C Evans, Raymond Evers.   

Abstract

Ethinylestradiol (EE) is one of the key constituents of oral contraceptives. Major metabolites of EE in humans are the glucuronide and sulfate conjugates, EE-3-O-glucuronide (EE-G) and EE-3-O-sulfate (EE-S). In the present study, transport of EE-G and EE-S by the human multidrug resistance proteins MRP1, MRP2, and MRP3 was investigated using inside-out membrane vesicles, isolated from Sf9 cells expressing human MRP1, MRP2, or MRP3. Vesicular uptake studies showed that EE-G was not a substrate for MRP1, whereas an ATP-dependent and saturable transport of [(3)H]EE-G was observed in MRP2 (K(m) of 35.1 +/- 3.5 microM) and MRP3 (K(m) of 9.2 +/- 2.3 microM) containing vesicles. EE-S was not transported by either MRP1, MRP2, or MRP3. However, low concentrations of EE-S stimulated MRP2-mediated uptake of ethacrynic acid glutathione. EE-S also stimulated MRP2 and MRP3-mediated uptake of 17beta-estradiol-17beta-D-glucuronide. Interestingly, EE-S stimulated strongly MRP2- and MRP3-mediated uptake of EE-G by increasing its apparent transport affinity, whereas no reciprocal stimulation of EE-S uptake by EE-G was observed. These data indicate that EE-S allosterically stimulates MRP2- and MRP3-mediated transport of EE-G and is not cotransported with EE-G. Our studies demonstrate specific active transport of a pharmacologically relevant drug conjugate by human MRP2 and MRP3, involving complex interactions with other organic anions. We also suggest that caution needs to be taken when using only competition studies as screening tools to identify substrates or inhibitors of MRP-mediated transport.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14722317     DOI: 10.1124/jpet.103.062091

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  25 in total

Review 1.  Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug.

Authors:  Hongjian Zhang; Donghui Cui; Bonnie Wang; Yong-Hae Han; Praveen Balimane; Zheng Yang; Michael Sinz; A David Rodrigues
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

2.  Hepatobiliary transport of YM466, a novel factor Xa inhibitor, in rats.

Authors:  Yuji Mano; Takashi Usui; Hidetaka Kamimura
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2006 Apr-Jun       Impact factor: 2.441

3.  Prediction of Drug Clearance from Enzyme and Transporter Kinetics.

Authors:  Priyanka R Kulkarni; Amir S Youssef; Aneesh A Argikar
Journal:  Methods Mol Biol       Date:  2021

4.  Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin.

Authors:  Thomayant Prueksaritanont; Xiaoyan Chu; Raymond Evers; Stephanie O Klopfer; Luzelena Caro; Prajakti A Kothare; Cynthia Dempsey; Scott Rasmussen; Robert Houle; Grace Chan; Xiaoxin Cai; Robert Valesky; Iain P Fraser; S Aubrey Stoch
Journal:  Br J Clin Pharmacol       Date:  2014-09       Impact factor: 4.335

5.  Nucleotide binding to the human multidrug resistance protein 3, MRP3.

Authors:  Andrea D Hoffman; Ina L Urbatsch; Pia D Vogel
Journal:  Protein J       Date:  2010-07       Impact factor: 2.371

6.  Molecular expression and functional evidence of a drug efflux pump (BCRP) in human corneal epithelial cells.

Authors:  Pradeep K Karla; Ravinder Earla; Sagar H Boddu; Thomas P Johnston; Dhananjay Pal; Ashim Mitra
Journal:  Curr Eye Res       Date:  2009-01       Impact factor: 2.424

Review 7.  Multidrug resistance-associated proteins 3, 4, and 5.

Authors:  Piet Borst; Cornelia de Wolf; Koen van de Wetering
Journal:  Pflugers Arch       Date:  2006-04-04       Impact factor: 3.657

8.  Enhanced corneal absorption of erythromycin by modulating P-glycoprotein and MRP mediated efflux with corticosteroids.

Authors:  Sudharshan Hariharan; Sriram Gunda; Gyan P Mishra; Dhananjay Pal; Ashim K Mitra
Journal:  Pharm Res       Date:  2008-10-29       Impact factor: 4.200

9.  Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation.

Authors:  Matthew L Rizk; Robert Houle; Grace Hoyee Chan; Mike Hafey; Elizabeth G Rhee; Xiaoyan Chu
Journal:  Antimicrob Agents Chemother       Date:  2013-12-02       Impact factor: 5.191

10.  Metabolism and renal elimination of gaboxadol in humans: role of UDP-glucuronosyltransferases and transporters.

Authors:  Xiao-Yan Chu; Yuexia Liang; Xiaoxin Cai; Karla Cuevas-Licea; Ronda K Rippley; Kelem Kassahun; Magang Shou; Matthew P Braun; George A Doss; M Reza Anari; Raymond Evers
Journal:  Pharm Res       Date:  2008-12-11       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.